Colonic Neoplasms Clinical Trial
— Crypto-KOfficial title:
Role of the Protozoa Cryptosporidium in the Development of Colorectal Cancer in Humans
NCT number | NCT04332705 |
Other study ID # | RC-P0091 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 30, 2020 |
Est. completion date | December 30, 2024 |
It has been reported that Cryptosporidium parvum, a species of a protozoan frequently isolated from humans and animals, is able to induce digestive adenocarcinoma in a rodent model. Consistently, some epidemiological studies have reported an association with cryptosporidiosis in patients with colorectal adenocarcinoma. However, the correlation between cryptosporidiosis and human digestive cancer remains unclear at this time, and it is not known whether this intracellular parasite, considered an opportunistic agent, is able to induce gastrointestinal malignancies in humans. In order to add new arguments for a probable association between cryptosporidiosis and digestive human cancer, the main aim of this study is to determine prevalence and to identify species of Cryptosporidium among a French digestive cancer population.
Status | Recruiting |
Enrollment | 324 |
Est. completion date | December 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Cases: - Age = 18 years old - Patients with colonic adenocarcinoma/intraepithelial neoplasia diagnosed prior to chemotherapy or radiotherapy who will undergo scheduled surgery. Patients with rectal cancer with indication for neoadjuvant treatment will still be included, but only biopsies used for diagnosis will be used - Patient capable of receiving informed information - Written informed consent - Affiliation to a social security scheme Controls: - Age = 18 years old - Patients with endoscopic indication for benign pathology - Patients with indication for colectomy for benign pathology - Patients with digestive cancer (stomach, oesophagus, biliary, pancreatic, etc.) of any type other than colorectal cancer before chemotherapy or radiotherapy - Patient capable of receiving informed information - Written informed consent - Affiliation to a social security scheme Exclusion Criteria: - Patients undergoing pre-operative chemotherapy. - Patients who have already had chemotherapy for less than one year or other immunosuppressive treatment |
Country | Name | City | State |
---|---|---|---|
France | Groupement des Hôpitaux de l'Institut Catholique de Lille | Lomme | Nord |
Lead Sponsor | Collaborator |
---|---|
Lille Catholic University | Institut Pasteur de Lille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of Cryptosporidium | A biopsy or a surgical sample will be collected from every participant which will be then screened for Cryptosporidium using a Polymerase chain reaction (PCR) in order to obtain a prevalence of positive individuals | 3 years | |
Secondary | Rate of occurrence of parasite development in the tumoral zone (yes/no) compared to the peri-tumoral zone. | A biopsy or a surgical sample containing the tumoral and peri-tumoral areas will be collected only from the cases which will be then screened for Cryptosporidium using PCR | 3 years | |
Secondary | Significance of the association between the histological grade of the lesion and the Cryptosporidium species | Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the Cryptosporidium species.The main species of Cryptosporidium infecting humans are C. parvum and C. hominis, however, other species can also infect humans. | 3 years | |
Secondary | Significance of the association between the histological grade of the lesion and the parasitic charge in tissues | Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the parasitic charge in the tissues that will be determined by quantitative polymerase chain reaction (qPCR) | 3 years | |
Secondary | The rate of change in the expression or localization of certain markers known or suspected to be involved in the process of carcinogenesis. | Some markers known to be associated to cancer development will be explored such as: Beta-catenin, P53, APC (adenomatous polyposis coli), etc. | 3years | |
Secondary | The association between the rate of lymphocytes (CD3, CD4, CD8, CD19 and CD4/CD8 ratio) and the presence of parasites in biopsies or surgical specimens | Because Cryptosporidium is an opportunistic agent that causes significant morbidity and mortality in immunocompromised patients, it is possible that individuals with malignancies, have a higher risk of developing infection with this parasite, especially when their immunosuppression is more severe. To rule out this possibility this association will be determined. | 3 years | |
Secondary | Rate of development of a neoplastic lesion in the human explants | A three-dimensional culture model will be developed using colon samples from healthy tissues of several control patients. An experimental Cryptosporidium infection will be tested in order to determine the development of neoplastic lesions in these human explants. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03746353 -
Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer
|
N/A | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT06041945 -
Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology
|
N/A | |
Not yet recruiting |
NCT02688699 -
Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract
|
Phase 4 | |
Not yet recruiting |
NCT03175146 -
A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely
|
N/A | |
Completed |
NCT02529007 -
Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening
|
N/A | |
Not yet recruiting |
NCT01929499 -
Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
|
Phase 2 | |
Completed |
NCT01681472 -
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT00535652 -
Concentration of Ertapenem in Colorectal Tissue
|
Phase 4 | |
Terminated |
NCT00267787 -
Molecular Genetic and Pathological Studies of Anal Tumors
|
||
Completed |
NCT05498051 -
Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.
|
N/A | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03314896 -
Laparoscopic Surgery for T4 Tumor of the Colon Cancer (LST4C Trial)
|
N/A | |
Not yet recruiting |
NCT02852915 -
Laparoscopic Surgery for T4 Tumor of the Colon Cancer
|
Phase 3 | |
Not yet recruiting |
NCT02777437 -
Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00997802 -
Japanese National Computed Tomographic (CT) Colonography Trial
|
N/A | |
Completed |
NCT01056913 -
NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
|
Phase 4 | |
Completed |
NCT00470782 -
Aerobic Capacity and Body Composition in Colon Cancer Patients
|
N/A | |
Completed |
NCT00537901 -
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
|
N/A |